Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., listed on Nasdaq under the ticker UPTD, filed an 8-K with the Securities and Exchange Commission on June 3, 2025, under accession number 0001213900-25-050329. The clinical-stage biopharmaceutical company, which concentrates on immunotherapy and oncology, reached its current public status through a SPAC business combination and remains an active reporting entity under post-merger SEC disclosure requirements. Operating in the life sciences and biotechnology sector, Estrella Immunopharma is among the de-SPAC companies continuing to meet ongoing filing obligations in 2025. For the complete filing breakdown, sponsor history, and deal timeline for UPTD, sign up for full data access at SpacDesk.